Where Hollywood magic meets AI intelligence — Hong Kong becomes the new stage for virtual humans
Updated
January 28, 2026 1:42 PM
William Wong, Chairman and CEO of Digital Domain. PHOTO: YORKE YU
In an era where pixels and intelligence converge, few companies bridge art and science as seamlessly as Digital Domain. Founded three decades ago by visionary filmmaker James Cameron, the company built its name through cinematic wizardry—bringing to life the impossible worlds of Titanic, The Curious Case of Benjamin Button and the Marvel universe. But today, its focus has evolved far beyond Hollywood: Digital Domain is reimagining the future of AI-driven virtual humans—and it’s doing so from right here in Hong Kong.
.jpg)
“AI and visual technology are merging faster than anyone imagined,” says William Wong, Chairman and CEO of Digital Domain. “For us, the question is not whether AI will reshape entertainment—it already has. The question is how we can extend that power into everyday life.”
Though globally recognized for its work on blockbuster films and AAA games, Digital Domain’s story is also deeply connected to Asia. A Hong Kong–listed company, it operates a network of production and research centers across North America, China and India. In 2024, it announced a major milestone—setting up a new R&D hub at Hong Kong Science Park focused on advancing artificial intelligence and virtual human technologies. “Our roots are in visual storytelling, but AI is unlocking a new frontier,” Wong says. “Hong Kong has been very proactive in promoting innovation and research, and with the right partnerships, we see real potential to make this a global R&D base.”
Building on that commitment, the company plans to invest about HK$200 million over five years, assembling a team of more than 40 professional talents specializing in computer vision, machine learning and digital production. For now, the team is still growing and has room to expand. “Talent is everything,” says Wong. “We want to grow local expertise while bringing in global experience to accelerate the learning curve.”
Digital Domain’s latest chapter revolves around one of AI’s most fascinating frontiers: the creation of virtual humans.
These are hyperrealistic, AI-powered virtual humans capable of speaking, moving and responding in real time. Using the advanced motion-capture and rendering techniques that transformed Hollywood visual effects, the company now builds digital personalities that appear on screens and in physical environments—serving in media, education, retail and even public services.
One of its most visible projects is “Aida”, the AI-powered presenter who delivers nightly weather reports on the Radio Television Hong Kong (RTHK). Another initiative, now in testing, will soon feature AI-powered concierges greeting travelers at airports, able to communicate in multiple languages and provide real-time personalized services. Similar collaborations are under way in healthcare, customer service and education.
“What’s exciting,” says Wong, “is that our technologies amplify human capability, helping to deliver better experiences, greater efficiency and higher capacity. AI-powered virtual humans can interact naturally, emotionally and in any language. They can help scale creativity and service, not replace it.”
To make that possible, Digital Domain has designed its system for compatibility and flexibility. It can connect to major AI models—from OpenAI and Google to Baidu—and operate across cloud platforms like AWS, Alibaba Cloud and Microsoft Azure. “It’s about openness,” says Wong. “Our clients can choose the AI brain that best fits their business.”
Establishing a permanent R&D base in Hong Kong marks a turning point for the company—and, in a broader sense, for the city’s technology ecosystem. With the support of the Office for Attracting Strategic Enterprises (OASES) in Hong Kong, Digital Domain hopes to make the city a creative hub where AI meets visual arts. “Hong Kong is the perfect meeting point,” Wong says. “It combines international exposure with a growing innovation ecosystem. We want to make it a hub for creative AI.”
As part of this effort, the company is also collaborating with universities such as the University of Hong Kong, City University of Hong Kong and Hong Kong Baptist University to co-develop new AI solutions and nurture the next generation of engineers. “The goal,” Wong notes, “is not just R&D for the sake of research—but R&D that translates into real-world impact.”
The collaboration with OASES underscores how both the company and the city share a vision for innovation-led growth. As Peter Yan King-shun, Director-General of OASES, notes, the initiative reflects Hong Kong’s growing strength as a global innovation and technology hub. “OASES was set up to attract high-potential enterprises from around the world across key sectors such as AI, data science, and cultural and creative technology,” he says. “Digital Domain’s new R&D center is a strong example of how Hong Kong can combine world-class talent, technology and creativity to drive innovation and global competitiveness.”
Digital Domain’s story mirrors the evolution of Hong Kong’s own innovation landscape—where creativity, technology and global ambition converge. From the big screen to the next generation of intelligent avatars, the company continues to prove that imagination is not bound by borders, but powered by the courage to reinvent what’s possible.
Keep Reading
A closer look at how machine intelligence is helping doctors see cancer in an entirely new light.
Updated
January 8, 2026 6:33 PM
Serratia marcescens colonies on BTB agar medium. PHOTO: UNSPLASH
Artificial intelligence is beginning to change how scientists understand cancer at the cellular level. In a new collaboration, Bio-Techne Corporation, a global life sciences tools provider, and Nucleai, an AI company specializing in spatial biology for precision medicine, have unveiled data from the SECOMBIT clinical trial that could reshape how doctors predict cancer treatment outcomes. The results, presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, highlight how AI-powered analysis of tumor environments can reveal which patients are more likely to benefit from specific therapies.
Led in collaboration with Professor Paolo Ascierto of the University of Napoli Federico II and Istituto Nazionale Tumori IRCCS Fondazione Pascale, the study explores how spatial biology — the science of mapping where and how cells interact within tissue — can uncover subtle immune behaviors linked to survival in melanoma patients.
Using Bio-Techne’s COMET platform and a 28-plex multiplex immunofluorescence panel, researchers analyzed 42 pre-treatment biopsies from patients with metastatic melanoma, an advanced stage of skin cancer. Nucleai’s multimodal AI platform integrated these imaging results with pathology and clinical data to trace patterns of immune cell interactions inside tumors.
The findings revealed that therapy sequencing significantly influences immune activity and patient outcomes. Patients who received targeted therapy followed by immunotherapy showed stronger immune activation, marked by higher levels of PD-L1+ CD8 T-cells and ICOS+ CD4 T-cells. Those who began with immunotherapy benefited most when PD-1+ CD8 T-cells engaged closely with PD-L1+ CD4 T-cells along the tumor’s invasive edge. Meanwhile, in patients alternating between targeted and immune treatments, beneficial antigen-presenting cell (APC) and T-cell interactions appeared near tumor margins, whereas macrophage activity in the outer tumor environment pointed to poorer prognosis.
“This study exemplifies how our innovative spatial imaging and analysis workflow can be applied broadly to clinical research to ultimately transform clinical decision-making in immuno-oncology”, said Matt McManus, President of the Diagnostics and Spatial Biology Segment at Bio-Techne.
The collaboration between the two companies underscores how AI and high-plex imaging together can help decode complex biological systems. As Avi Veidman, CEO of Nucleai, explained, “Our multimodal spatial operating system enables integration of high-plex imaging, data and clinical information to identify predictive biomarkers in clinical settings. This collaboration shows how precision medicine products can become more accurate, explainable and differentiated when powered by high-plex spatial proteomics – not limited by low-plex or H&E data alone”.
Dr. Ascierto described the SECOMBIT trial as “a milestone in demonstrating the possible predictive power of spatial biomarkers in patients enrolled in a clinical study”.
The study’s broader message is clear: understanding where immune cells are and how they interact inside a tumor could become just as important as knowing what they are. As AI continues to map these microscopic landscapes, oncology may move closer to genuinely personalized treatment — one patient, and one immune network, at a time.